A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 14 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2011 New trial record